Key Quantitative Figures

Financial Results (Standalone - FY2025-26)

  • Total Income: ₹18,893.63 lakhs
  • Total Expenses: ₹16,635.55 lakhs
  • Profit before tax: ₹1,506.63 lakhs
  • Tax Expense: ₹385.24 lakhs (Current Tax: ₹362.36 lakhs, Deferred Tax: ₹22.88 lakhs)
  • Net Profit after tax: ₹1,121.39 lakhs
  • Other Comprehensive Income: -₹5.13 lakhs
  • Total Comprehensive Income: ₹1,116.26 lakhs
  • Paid-up Equity Share Capital: ₹1,038.62 lakhs (post-ESOP allotment)
  • Earnings Per Share (Basic & Diluted): ₹10.79

Financial Results (Consolidated - FY2025-26)

  • Total Income: ₹18,893.63 lakhs
  • Profit/(Loss) before tax: -₹2,792.02 lakhs
  • Tax Expense: ₹362.36 lakhs
  • Net Profit/(Loss) after tax: -₹2,466.34 lakhs
  • Other Comprehensive Income: -₹0.55 lakhs
  • Total Comprehensive Income: -₹2,466.89 lakhs
  • Earnings Per Share (Basic & Diluted): -₹23.84 / -₹23.78

ESOP Allotment

  • Number of shares allotted: 25,000 equity shares of face value ₹10 each
  • Exercise Price: ₹10 per share
  • Money realized: ₹2,50,000
  • Distinctive Numbers: 10399468 to 10424467
  • Paid-up capital increase: From ₹10,38,61,540 to ₹10,41,11,540
  • Diluted EPS post-allotment: ₹10.72 (calculated using FY 2025-26 earnings)

Segment-wise Performance (Consolidated - FY2025-26)

  • Capsules Segment Revenue: ₹17,377.09 lakhs; Segment Result: ₹2,081.91 lakhs profit
  • API Segment Revenue: ₹1,343.37 lakhs; Segment Result: -₹3,132.83 lakhs loss

Dates of Action

  • Board Meeting Date: May 27, 2026 (commenced at 03:13 PM, concluded at 07:18 PM)
  • ESOP Allotment Date: May 27, 2026
  • Financial Year End: March 31, 2026
  • Effective date for new Company Secretary: May 27, 2026
  • Effective date for Director re-appointment: July 28, 2026 (subject to shareholder approval)

Parties Involved

  • Subsidiaries: Natural Phyto Pharma Private Limited, Natural Biogenex Private Limited
  • Statutory Auditors: P. Chandrasekar LLP
  • Internal Auditor: Mallya & Mallya, Chartered Accountants (appointed for FY 2026-27)
  • Regulators: BSE Limited, National Stock Exchange of India Limited, SEBI
  • Key Personnel:
  • Mr. Shri Laxminarayana Moondra (DIN: 00214298) - Re-appointed Whole-time Director
  • Mr. Akshay Dutta (M.No: A80481) - Appointed Company Secretary & Compliance Officer
  • Mr. Sunil Laxminarayana Mundra (DIN: 00214304) - Managing Director

Purpose/Rationale

  • To comply with SEBI LODR Regulations for disclosing board meeting outcomes and financial results.
  • To inform about the allotment of shares under the Employee Stock Option Plan 2025.
  • To seek shareholder approval for the re-appointment and remuneration revision of a Whole-time Director.

Financial/Operational Impact

  • The allotment of 25,000 shares has increased the paid-up share capital and caused minor dilution.
  • One manufacturing unit was temporarily shut down from December 26, 2025, due to a regulatory issue and resumed operations on January 30, 2026.
  • The subsidiary Natural Biogenex Private Limited started commercial operations on March 31, 2025, and incurred losses in FY2025-26 as revenue potential is yet to be achieved.

Capital Structure Impact

  • Increase in paid-up equity share capital from ₹10,38,61,540 to ₹10,41,11,540 due to ESOP allotment.
  • The new shares rank pari-passu with existing equity shares.

Cash Flow Implications

  • Inflow of ₹2,50,000 from exercise of ESOP options.

Forward-looking Guidance

  • The re-appointment of Mr. Shri Laxminarayana Moondra as Whole-time Director and revision of his remuneration is subject to shareholder approval at the ensuing Annual General Meeting.

Material Changes

  • The consolidated results show a significant loss in FY2025-26 (-₹2,466.34 lakhs) compared to a profit in FY2024-25 (₹61.74 lakhs), primarily due to losses in the API segment.
  • Standalone performance remained profitable with a net profit of ₹1,121.39 lakhs in FY2025-26.

Auditor's Opinion

  • P. Chandrasekar LLP issued an unmodified (clean) audit opinion on both the standalone and consolidated financial results.

Investor Complaints

  • No investor complaints were pending or received during the quarter ended March 31, 2026.